1 October 2023
Ropes & Gray Represents Novo Nordisk in AI-Based Cardiometabolic Drug Discovery Collaboration with Valo Health Worth Up to $2.7 Billion
Advising firms
Deal team
2 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Hannah England | Ropes & Gray | Partner | life sciences licensing | Not stated |
| Ian Nilsen | Ropes & Gray | Associate | life sciences licensing | Not stated |
Stated terms
- Stated value
- USD 2.70bn ($2.7 billion)
- What the figure measures
- Total transaction value
- Client
- Novo NordiskBuy-side
- Counterparties
- Valo Health (Sell-side)